Immune checkpoint inhibitors targeting various immune checkpoints, such as CTLA-4, PD-1, PD-L1, and B7-H4, have been developed for endometrial cancer and have shown efficacy in improving patient survival rates (30, 41, 42). This evidence concerns the gene VTCN1 and endometrial cancer.